FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jean-Pierre Aboulker

Research Profile

Disorders

Living Beings

HIV-1

Chemicals & Drugs

Procedures

Physiology

Concepts & Ideas

Co-author Network

Publications

TOP 3
Christine Durier; Pierre-Marie Girard; Odile Launay; Yves Lévy; Frédéric Lucht; Thierry May; Christian Michelet; Agathe Rami; François Roman; Jean-Pierre Aboulker; Jean-François Delfraissy; Corinne Desaint
Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults.
Nicole Le Corre; Vincent Meiffrédy; Emmanuel Morelon; Claire Pouteil-Noble; Fréderic Thibault; David Bottigioli; Remi Cahen; Isabelle Charreau; Sameh Daoud; Cécile Dollinger; Jean-Pierre Aboulker; Brigitte Autran; Benoit Barrou
Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Constance Delaugerre; Bruno Marchou; thierry may; Jean-Michel Molina; M L Nere; François SIMON; Jean-Pierre Aboulker; J Braun; Isabelle Charreau; Nathalie de Castro; Séverine Delarue
Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jean-Pierre Aboulker (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Christine Durier; Pierre-Marie Girard; Odile Launay; Yves Lévy; Frédéric Lucht; Thierry May; Christian Michelet; Agathe Rami; François Roman; Jean-Pierre Aboulker; Jean-François Delfraissy; Corinne Desaint
Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults.
AIDS (London, England) 2013;27(1):87-93.
2012: Nicole Le Corre; Vincent Meiffrédy; Emmanuel Morelon; Claire Pouteil-Noble; Fréderic Thibault; David Bottigioli; Remi Cahen; Isabelle Charreau; Sameh Daoud; Cécile Dollinger; Jean-Pierre Aboulker; Brigitte Autran; Benoit Barrou
Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Vaccine 2012;30(52):7522-8.
2012: Constance Delaugerre; Bruno Marchou; thierry may; Jean-Michel Molina; M L Nere; François SIMON; Jean-Pierre Aboulker; J Braun; Isabelle Charreau; Nathalie de Castro; Séverine Delarue
Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.
HIV medicine 2012;13(9):517-25.
2012: Stéphanie Trancart; Jean-Pierre Aboulker; Muriel Bocquentin; Isabelle Charreau; Jacques Izopet; Bruno Marchou; Jean-Michel Molina; Anne-Marie Taburet; Philippe Tangre
Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.
Antimicrobial agents and chemotherapy 2012;56(3):1655-7.
2012: Nicolas Lorente; Jean-Michel Molina; Jean-Pierre Aboulker; Christian Andreo; Catherine Capitant; Maria Patrizia Carrieri; Emmanuel Cook; Lionel Fugon; Jean-Marie Le Gall; Bruno Spire
Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
AIDS care 2012;24(4):468-77.
2011: Vassilis Tsatsaris; Jean-Pierre Aboulker; Sophie Bulifon; Catherine Capitant; Corine Chazallon; Evelyne Jacqz-Aigrain; Fabrice Lainé; Odile Launay; Fanny Lewin; Olivier Picone; Patrice Poulain; Didier Riethmuller; Thomas Schmitz
Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.
Annals of internal medicine 2011;155(11):733-41.
2011: E R Feeney; R L Goodall; Patrick W G Mallon; Vincent Meiffrédy; N O'Brien; Patrick Yeni; Jean-Pierre Aboulker; Corine Chazallon; D A Cooper
Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).
HIV medicine 2011;12(10):602-9.
2011: Sébastien Gallien; François Jeanblanc; Isabelle Madelaine-Chambrin; thierry may; Jean-Michel Molina; Jacques Reynes; Renaud Verdon; Jean-Pierre Aboulker; Joséphine Braun; Isabelle Charreau; pierre de truchis; Constance Delaugerre
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
The Journal of antimicrobial chemotherapy 2011;66(9):2099-106.
2011: Odile Launay; Pierre Loulergue; Gilles Pialoux; François Raffi; David Rey; Jacques Reynes; François Roman; Jean-Pierre Aboulker; Faiza Ajana; Nathalie Colin de Verdière; Jean-François Delfraissy; Corinne Desaint; Jeanne-Marie Devaster; Christine Durier; Xavier Duval; Valérie Foubert; Jade Ghosn; Christine Jacomet
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.
The Journal of infectious diseases 2011;204(1):124-34.
2011: Pierre Delobel; Martine Dubois; Jacques Izopet; Bruno Marchou; Patrice Massip; Jean-Michel Molina; Florence Nicot; Adrien Saliou; Anne-Marie Taburet; Philippe Tangre; Stéphanie Trancart; Jean-Pierre Aboulker
Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure.
PloS one 2011;6(6):e21655.
2010: K Boyd; David T Dunn; H Castro; Diana M Gibb; Trinh Duong; Jean-Pierre Aboulker; M Bulterys; Mario Cortina Borja; C Gabiano; L Galli; Carlo Giaquinto; D R Harris; M HugheS; R McKinney; L Mofenson; J Moye; M L Newell; Savita Pahwa; P Palumbo; C Rudin; Mike Sharland; W Shearer; B Thompson; Pat A Tookey
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children.
AIDS (London, England) 2010;24(8):1213-7.
2008: Isabelle Charreau; Grégoire Jeanblanc; Philippe Tangre; Laurence Boyer; Marine Saouzanet; Bruno Marchou; Jean Michel Molina; Jean-Pierre Aboulker; Isabelle Durand-Zaleski
Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: a substudy of the ANRS 106 Window Trial.
Journal of acquired immune deficiency syndromes (1999) 2008;49(4):416-21.
2008: Jacques Izopet; Bruno Marchou; Isabelle Charreau; Karine Sauné; Philippe Tangre; Jean-Michel Molina; Jean-Pierre Aboulker
HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Antiviral therapy 2008;13(4):537-45.
2007: Christine Durier; Catherine Capitant; Anne-Sophie Lascaux; Cécile Goujard; Eric Oksenhendler; Isabelle Poizot-Martin; Jean-Paul Viard; Laurence Weiss; Emmanuelle Netzer; Jean-François Delfraissy; Jean-Pierre Aboulker; Yves Lévy
Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
AIDS (London, England) 2007;21(14):1887-97.
2007: Cécile Goujard; Fabienne Marcellin; Houria Hendel-Chavez; Marianne Burgard; Vincent Meiffrédy; Alain Venet; Christine Rouzioux; Yassine Taoufik; Raphaelle El Habib; Maria Beumont-Mauviel; Jean-Pierre Aboulker; Yves Lévy; Jean-François Delfraissy
Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.
AIDS research and human retroviruses 2007;23(9):1105-13.
2007: Bruno Marchou; Philippe Tangre; Isabelle Charreau; Jacques Izopet; Pierre-Marie Girard; Thierry May; Jean-Marie Ragnaud; Jean-Pierre Aboulker; Jean-Michel Molina
Intermittent antiretroviral therapy in patients with controlled HIV infection.
AIDS (London, England) 2007;21(4):457-66.
2007: Laurence Gérard; Corine Chazallon; Anne-Marie Taburet; Pierre-Marie Girard; Jean-Pierre Aboulker; Christophe Piketty
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Antiviral therapy 2007;12(1):31-9.
2006: Patrick Yeni; David A Cooper; Jean-Pierre Aboulker; A G Babiker; D Carey; Janet Darbyshire; Marco Floridia; P M Girard; Ruth L Goodall; Malcolm H Hooker; A Mijch; Vincent Meiffredy; B Salzberger
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.
Lancet 2006;368(9532):287-98.
2006: Assia Samri; Christine Durier; Alejandra Urrutia; I Sanchez; H Gahery-Segard; S Imbart; Martine Sinet; E Tartour; Jean-Pierre Aboulker; Brigitte Autran; Alain Venet
Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.
Clinical and vaccine immunology : CVI 2006;13(6):684-97.
2006: Philippe Flandre; Claire Pinçon; Jean-Pierre Aboulker; Françoise Brun-Vézinet; Gilles Pialoux; François Raffi; Diane Descamps
Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials.
HIV clinical trials 2006;7(3):116-24.
2006: Anne-Geneviève Marcelin; Corine Chazallon; Laurence Gérard; Yacine Saïdi; Jean-Pierre Aboulker; Pierre-Marie Girard; Vincent Calvez; Christophe Piketty
External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.
Journal of acquired immune deficiency syndromes (1999) 2006;42(1):127-8.
2006: Christine Durier; Odile Launay; Vincent Meiffrédy; Yacine Saïdi; Dominique Salmon; Yves Lévy; Jean-Gérard Guillet; Gilles Pialoux; Jean-Pierre Aboulker
Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults.
AIDS (London, England) 2006;20(7):1039-49.
2006: Yves Lévy; Christine Durier; Anne-Sophie Lascaux; Vincent Meiffrédy; Hanne Gahéry-Ségard; Cécile Goujard; Christine Rouzioux; Martine Resch; Jean-Gérard Guillet; Michel D Kazatchkine; Jean-François Delfraissy; Jean-Pierre Aboulker
Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals.
AIDS (London, England) 2006;20(3):405-13.
2006: Hannah Green; Diana M Gibb; Alexandra Compagnucci; Vania Giacomet; Anita De Rossi; Lynda Harper; Yacine Saïdi; Guido Gattinara Castelli; Deenan Pillay; Abdel G Babiker; Jean-Pierre Aboulker; Hermione Lyall; Lee Bacheler; A Sarah Walker; Marianne Debré; Raffaella Rosso; David Burger; Marinella Della Negra; David T Dunn; Carlo Giaquinto
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
Antiviral therapy 2006;11(7):857-67.
2006: Christophe Piketty; Laurence Gérard; Corine Chazallon; Anne-Geneviève Marcelin; François Clavel; Anne-Marie Taburet; Vincent Calvez; Isabelle Madelaine-Chambrin; Jean-Michel Molina; Jean-Pierre Aboulker; Pierre-Marie Girard
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Antiviral therapy 2006;11(2):213-21.
2005: Céline Verstuyft; Fabienne Marcellin; Laurence Morand-Joubert; Odile Launay; Karl Brendel; France Mentré; Gilles Peytavin; Laurence Gérard; Laurent Becquemont; Jean-Pierre Aboulker
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.
AIDS (London, England) 2005;19(18):2127-31.
2005: Bruno Hoen; Isabelle Fournier; Christine Lacabaratz; Marianne Burgard; Isabelle Charreau; Marie-Laure Chaix; Jean-Michel Molina; Jean-Michel Livrozet; Alain Venet; François Raffi; Jean-Pierre Aboulker; Christine Rouzioux
Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial.
Journal of acquired immune deficiency syndromes (1999) 2005;40(3):307-16.
2005: Diane Descamps; Véronique Joly; Philippe Flandre; Gilles Peytavin; Vincent Meiffrédy; Séverine Delarue; STEPHANE LASTERE; Jean-Pierre Aboulker; Patrick Yeni; Françoise Brun-Vézinet
Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2005;33(2):99-103.
2005: Laurence Morand-Joubert; Fabienne Marcellin; Odile Launay; Sonia Guiramand-Hugon; Laurence Gérard; Patrick Yeni; Jean-Pierre Aboulker
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
Journal of acquired immune deficiency syndromes (1999) 2005;38(3):268-76.
2005: Yves Lévy; Hanne Gahéry-Ségard; Christine Durier; Anne-Sophie Lascaux; Cécile Goujard; Vincent Meiffrédy; Christine Rouzioux; Raphaelle El Habib; Maria Beumont-Mauviel; Jean-Gérard Guillet; Jean-François Delfraissy; Jean-Pierre Aboulker
Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
AIDS (London, England) 2005;19(3):279-86.
2004: Christophe Piketty; Laurence Gérard; Corine Chazallon; Vincent Calvez; François Clavel; Anne-Marie Taburet; Pierre-Marie Girard; Jean-Pierre Aboulker
Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures.
AIDS (London, England) 2004;18(10):1469-71.
2004: Anne-Marie Taburet; Christophe Piketty; Corine Chazallon; Isabelle Vincent; Laurence Gérard; Vincent Calvez; François Clavel; Jean-Pierre Aboulker; Pierre-Marie Girard
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2004;48(6):2091-6.
2004: Jean-Pierre Aboulker; Abdel G Babiker; Marie-Laure Chaix; Alexandra Compagnucci; Janet Darbyshire; M Debré; Albert Faye; Carlo Giaquinto; Diana M Gibb; Lynda Harper; Yacine Saïdi; A Sarah Walker
Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.
AIDS (London, England) 2004;18(2):237-45.
2003: Serge Diagbouga; Corine Chazallon; Michel D Kazatchkine; Philippe Van de Perre; André Inwoley; Souleymane M'Boup; Mireille Prince David; Aoua Thiéro Ténin; Robert Soudré; Jean-Pierre Aboulker; Laurence Weiss
Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12-26 study.
AIDS (London, England) 2003;17(15):2201-8.
2003: Nguyen Thi Hoang Lan; Patricia Recordon-Pinson; Pham Van Hung; Nguyen Thi Vy Uyen; Truong Thi Xuan Lien; Huynh Tan Tien; Isabelle Garrigue; Marie-Hélène Schrive; Isabelle Pellegrin; Marie-Edith Lafon; Jean-Pierre Aboulker; Françoise Barré-Sinousi; Hervé J Fleury
HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01_AE and presence of major resistance mutations to antiretroviral drugs.
AIDS research and human retroviruses 2003;19(10):925-8.
2003: Yves Levy; Christine Durier; Roman Krzysiek; Claire Rabian; Catherine Capitant; Anne-Sophie Lascaux; Christophe Michon; Eric Oksenhendler; Laurence Weiss; Jean-Albert Gastaut; Cécile Goujard; Christine Rouzioux; Jean Maral; Jean-François Delfraissy; Dominique Emilie; Jean-Pierre Aboulker
Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial.
AIDS (London, England) 2003;17(3):343-51.
2003: Philippe Flandre; Diane Descamps; Véronique Joly; Vincent Meiffrédy; Catherine Tamalet; Jacques Izopet; Jean-Pierre Aboulker; Françoise Brun-Vézinet
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Antiviral therapy 2003;8(1):65-72.
2002: Diane Descamps; Philippe Flandre; Véronique Joly; Vincent Meiffrédy; Gilles Peytavin; Jacques Izopet; Catherine Tamalet; Ai-Feng Zeng; Marine Harel; STEPHANE LASTERE; Jean-Pierre Aboulker; Patrick Yéni; Françoise Brun-Vézinet
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Journal of acquired immune deficiency syndromes (1999) 2002;31(5):464-71.
2002: Véronique Joly; Philippe Flandre; Vincent Meiffredy; Nicolas Leturque; Marine Harel; Jean-Pierre Aboulker; Patrick Yeni
Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
AIDS (London, England) 2002;16(18):2447-54.
2002: Odile Launay; Laurence Gérard; Laurence Morand-Joubert; Philippe Flandre; Sonia Guiramand-Hugon; Véronique Joly; Gilles Peytavin; Agnès Certain; Claude Lévy; Stéphane Rivet; Christine Jacomet; Jean-Pierre Aboulker; Patrick Yéni
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;35(9):1096-105.
2002: Véronique Joly; Philippe Flandre; Vincent Meiffredy; Françoise Brun Vezinet; Jean-Albert Gastaut; Cécile Goujard; Gérard Remy; Diane Descamps; Annick Ruffault; Agnès Certain; Jean-Pierre Aboulker; Patrick Yeni
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Antimicrobial agents and chemotherapy 2002;46(6):1906-13.
2002: Philippe Flandre; François Raffi; Diane Descamps; Vincent Calvez; Gilles Peytavin; Vincent Meiffredy; Marine Harel; Sylvie Hazebrouck; Gilles Pialoux; Jean-Pierre Aboulker; Françoise Brun Vezinet
Final analysis of the Trilège induction-maintenance trial: results at 18 months.
AIDS (London, England) 2002;16(4):561-8.
2001: Daniel Scott-Algara; Jean-Pierre Aboulker; Christine Durier; Edgar Badell; Fabienne Marcellin; M Prud'homme; C Jouanne; Vincent Meiffredy; Françoise Brun Vezinet; Gilles Pialoux; François Raffi
CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.
Clinical and experimental immunology 2001;126(2):295-303.
2001: C Rabaud; Isabelle Charreau; S Izard; François Raffi; Vincent Meiffredy; Catherine Leport; F Guillemin; Patrick Yeni; Jean-Pierre Aboulker
Adverse reactions to cotrimoxazole in HIV-infected patients: predictive factors and subsequent HIV disease progression.
Scandinavian journal of infectious diseases 2001;33(10):759-64.
2000: Diane Descamps; Philippe Flandre; Vincent Calvez; Gilles Peytavin; Vincent Meiffredy; Gilles Collin; Constance Delaugerre; S Robert-Delmas; B Bazin; Jean-Pierre Aboulker; Gilles Pialoux; François Raffi; Françoise Brun-Vézinet
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
JAMA : the journal of the American Medical Association 2000;283(2):205-11.
1999: Yves Levy; Catherine Capitant; S Houhou; I Carriere; Jean-Paul Viard; Cécile Goujard; Jean-Albert Gastaut; Eric Oksenhendler; Laurence Boumsell; Elisabeth Gomard; Claire Rabian; Laurence Weiss; Jean-Gérard Guillet; Jean-François Delfraissy; Jean-Pierre Aboulker; M Seligmann
Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
Lancet 1999;353(9168):1923-9.
1999: François Raffi; Jacqueline Franck; Hervé Pelloux; F Derouin; Véronique Reliquet; P Ambroise-Thomas; Jean-Pierre Aboulker; Catherine Leport; Henri Dumon
Specific anti-toxoplasmic IgG antibody immunoblot profiles in patients with AIDS-associated Toxoplasma encephalitis.
Diagnostic microbiology and infectious disease 1999;34(1):51-6.
1999: Dominique Salmon-Céron; Anne-Marie Fillet; Jean-Pierre Aboulker; Laurence Gérard; Nadhira Houhou; I Carrière; J Ostinelli; Jean-Louis Vildé; Françoise Brun-Vézinet; Catherine Leport
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(4):901-5.
1999: Bernard Masquelier; Diane Descamps; I Carrière; Françoise Ferchal; Gilles Collin; M Denayrolles; Annick Ruffault; B Chanzy; Jacques Izopet; Claudine Buffet-Janvresse; M P Schmitt; Ester Race; Hervé J Fleury; Jean-Pierre Aboulker; Patrick Yeni; Françoise Brun-Vézinet
Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study.
Antiviral therapy 1999;4(2):69-77.
1998: Gilles Pialoux; François Raffi; Françoise Brun Vezinet; Vincent Meiffrédy; Philippe Flandre; J A Gastaut; Pierre Dellamonica; Patrick Yeni; Jean-François Delfraissy; Jean-Pierre Aboulker
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
The New England journal of medicine 1998;339(18):1269-76.
1998: Geneviève Chêne; Philippe Morlat; Catherine Leport; Richard Hafner; L Dequae; Isabelle Charreau; Jean-Pierre Aboulker; Benjamin J Luft; J Aubertin; Jean-Louis Vildé; Roger Salamon
Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group.
Controlled clinical trials 1998;19(3):233-48.
1998: Christophe Piketty; P Castiel; Laurent Belec; Dominique Batisse; Ali Si-Mohamed; Jacques Gilquin; Gustavo Gonzalez-Canali; D Jayle; Marina Karmochkine; Laurence Weiss; Jean-Pierre Aboulker; Michel D Kazatchkine
Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.
AIDS (London, England) 1998;12(7):745-50.
1997: Hervé Pelloux; J Dupouy-Camet; F Derouin; Jean-Pierre Aboulker; F Raffi
A multicentre prospective study for the polymerase chain reaction detection of Toxoplasma gondii DNA in blood samples from 186 AIDS patients with suspected toxoplasmic encephalitis. Bio-Toxo Study Group.
AIDS (London, England) 1997;11(15):1888-90.
1997: I P Coulaud; Marie-lise GOUGEON; Elisabeth Gomard; D Descamps; P Lebon; Jean-Pierre Aboulker; Bernard Bizzini; Daniel Zagury
A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunization.
AIDS (London, England) 1997;11(7):937-8.
1997: François Raffi; Jean-Pierre Aboulker; Christian Michelet; Véronique Reliquet; Hervé Pelloux; A Huart; Isabelle Poizot-Martin; P Morlat; B Dupas; J-M G Mussini; Catherine Leport
A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study Group.
AIDS (London, England) 1997;11(2):177-84.
1996: Véronique Joly; P Aubry; A Ndayiragide; I Carrière; E Kawa; N Mlika-Cabanne; Jean-Pierre Aboulker; J P Coulaud; Bernard Larouze; Patrick Yeni
Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(3):556-62.
1995: Dominique Salmon-Ceron; A Fontbonne; J Saba; T May; F Raffi; C Chidiac; O Patey; Jean-Pierre Aboulker; David H Schwartz; Jean-Louis Vildé
Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group.
The Journal of infectious diseases 1995;172(3):656-64.
1994: E Oksenhendler; I Charreau; C Tournerie; M Azihary; C Carbon; Jean-Pierre Aboulker
Toxoplasma gondii infection in advanced HIV infection.
AIDS (London, England) 1994;8(4):483-7.
1992: Jean-Pierre Aboulker; B Autran; K Beldjord; F Touraine; P Debre
Consistency of routine measurements of CD4+, CD8+ peripheral blood lymphocytes.
Journal of immunological methods 1992;154(2):155-61.